Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
Sponsor: Massachusetts General Hospital
Summary
The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study is evaluating immediate or delayed single-dose nonavalent HPV vaccination among women living with HIV who received prior HPV vaccination.
Official title: Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study.
Key Details
Gender
FEMALE
Age Range
16 Years - Any
Study Type
INTERVENTIONAL
Enrollment
778
Start Date
2024-10-14
Completion Date
2027-06
Last Updated
2026-01-12
Healthy Volunteers
No
Conditions
Interventions
GARDASIL®9
GARDASIL®9 or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
Menveo®/Menactra®
Menveo®/Menactra® or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
Locations (3)
Botswana Harvard Health Partnership
Gaborone, Botswana
Ministry of Health and Center for Family Health Research
Kigali, Kigali, Rwanda
Wits RHI, University of the Witwatersrand
Johannesburg, Gauteng, South Africa